Patent ID: 8487099

Claim:
A compound of the formula or a pharmaceutically acceptable salt thereof, wherein G is —O— or O—C—(R3) 2 each R 3 is taken together with the carbon atom to which they are bound to form a 3 to 8 membered cycloalkyl or heterocycloalkyl ring, said heterocycloalkyl ring comprising 1 to 3 ring members independently selected from the group consisting of: O, S, NR 2 , P(O)alkyl, P(O)Oalkyl, S(O), and S(O) 2 , and wherein the remaining ring members are selected from the group consisting of carbon and C(O); Spiro Ring (A) is selected from the group consisting of: cycloalkyl, cycloalkenyl, heterocycloalkyl, and heterocycloalkenyl, wherein: (a) said cycloalkyl ring (A) is a 3 to 8 carbon membered ring (including the carbon atom common to both rings (A) and (B)), and (b) said cycloalkenyl ring (A) is a 5 to 8 carbon membered ring (including the carbon atom common to both rings (A) and (B)) comprising one or two double bonds, provided that there is no double bond to the carbon common to Rings (A) and (B) and (c) said heterocycloalkyl Ring (A) is a 4 to 8 membered ring (including the carbon atom common to Rings (A) and (B)) comprising 1 to 3 ring members independently selected from the group consisting of: O, S, NR 2 , P(O)alkyl, P(O)Oalkyl, S(O), and S(O) 2 , and wherein the remaining ring members are independently selected from the group consisting of carbon and C(O), and (d) said heterocycloalkenyl Ring (A) is a 5 to 8 membered ring (including the carbon atom common to Rings (A) and (B)) comprising one or two double bonds, and comprising 1 to 3 ring members independently selected from the group consisting of: O, S, NR 2 , P(O)alkyl, P(O)Oalkyl, S(O), and S(O) 2 , and wherein the remaining ring members are independently selected from the group consisting of carbon and C(O), provided that there is no double bond to the carbon common to Rings (A) and (B), and (e) wherein said Spiro Ring (A) is optionally fused with an aryl ring, or is optionally fused with a heteroaryl ring, to form a fused Spiro Ring (A) moiety, and (f) wherein said Spiro Ring (A) is optionally substituted with 1 to 3 substituents independently selected from the group consisting of: alkyl, alkenyl, alkynyl, —CN, halo, —C(O)R 15 , —C(O)OR 15 , —C(O)N(R 15 )(R 16 ), —S(O)N(R 15 )(R 16 ), —S(O) 2 N(R 15 )(R 16 ), —C(═NOR 15 )R 16 , —P(O)(OR 15 )(OR 16 ), —OR 15 (e.g., —OCH 3 ), and —S(O) 2 R 15A (e.g., —S(O) 2 CH 3 ); R 6 and R 7 are each independently selected from the group consisting of: H, alkyl-, alkenyl-, alkynyl-, phenyl, pyridinyl or thiophenyl, wherein the alkyl, alkenyl, alkynyl, phenyl, pyridinyl or thiophenyl is optionally substituted with 1 to 5 independently selected R 21 groups selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxyl and halo; or R 6 and R 7 , together with the carbon atom to which they are bound, form 6-membered heterocycloalkyl fused to a phenyl; R 15 and R 16 are each independently selected from hydrogen, alkyl, alkenyl and alkynyl; and R 15A is selected from alkyl, alkenyl and alkynyl.